Effects of Oral Streptococci and Selected Probiotic Bacteria on the Pathogen Streptococcus Pyogenes: Viability, Biofilms, Molecular Functions, and Virulence Traits

Total Page:16

File Type:pdf, Size:1020Kb

Effects of Oral Streptococci and Selected Probiotic Bacteria on the Pathogen Streptococcus Pyogenes: Viability, Biofilms, Molecular Functions, and Virulence Traits Effects of oral streptococci and selected probiotic bacteria on the pathogen Streptococcus pyogenes: viability, biofilms, molecular functions, and virulence traits Dissertation zur Erlangung des akademischen Grades doctor rerum naturalium (Dr. rer. nat) der Mathematisch-Naturwissenschaftlichen Fakultät der Univesität Rostock vorgelegt von Catur Riani geb. am 13.08.1976 auf Pulau Sambu aus Indonesien Rostock, Januar 2009 urn:nbn:de:gbv:28-diss2009-0087-1 Prof. Johannes Knobloch (Gutachter / Reviewer) Universitätsklinikum Schleswig-Holstein Campus Lübeck Ratzeburger Allee 160 23538 Lübeck Prof. Dr. Hubert Bahl (Gutachter / Reviewer) Uni Rostock Institut für Biologie Albert Einstein Str. 3 18059 Rostock Prof. Dr. Regine Hakenbeck (Gutachter / Reviewer) Technische Universität Kaiserslautern FB Biologie P.-Ehrlich-Str. 67663 Kaiserslautern Prof. Dr. Andreas Podbielski (Gutachter & Betreuer / Reviewer & Supervisor) Uni Rostock Medizin Abt. für Medizinische Mikrobiologie, Virologie und Hygiene Schillingalle 70 18057 Rostock Abgabedatum / date of submission: 30 Januar 2009 Verteidigungsdatum / date of defence: 4 Mai 2009 “Gedruckt mit Unterstützung des Deutschen Akademischen Austauschdienstes” Table of content Table of content Abbreviations I. Introduction ........................................................................................................... 1 I.1 Streptococcus pyogenes as a human pathogen ............................................. 1 I.2 The physiological microflora of the upper respiratory tract ........................ 4 I.3 Streptococci and their value as upper airways probiotics ............................ 7 I.4 Aims of the present study ............................................................................. 10 II. Material and Methods ............................................................................................ 12 II.1 Material ........................................................................................................ 12 II.1.1 Bacterial strains ................................................................................ 12 II.1.2 Culture media for bacteria ................................................................ 12 II.1.3 Eukaryotic cells and media for cell culture ...................................... 13 II.1.4 Plasmid ............................................................................................. 14 II.1.5 Antibodies ........................................................................................ 14 II.1.6 Reagents and buffers ........................................................................ 14 II.1.7 Instruments ....................................................................................... 14 II.2 Methods ........................................................................................................ 15 II.2.1 Bacterial culture condition ............................................................... 15 II.2.2 Culture condition and preparation of eukaryotic cell culture ........... 16 II.2.3 DNA/RNA methods and manipulation ............................................ 16 II.2.3.1 S. pyogenes DNA preparation ........................................... 16 II.2.3.2 Plasmid isolation from E. coli ........................................... 17 II.2.3.3 HEp-2 cells RNA isolation ................................................ 17 II.2.3.4 DNA/RNA concentration measurement ............................ 18 II.2.3.5 Polymerase Chain Reaction (Mullis et al., 1986) ............. 18 II.2.3.6 DNA restriction digest ...................................................... 19 II.2.3.7 DNA ligation reaction ....................................................... 19 II.2.3.8 Agarose electrophoresis for DNA (Sambrook et al., 1989) 19 II.2.3.9 Construction of the S. pyogenes M6 sagA-luc reporter gene strain ......................................................................... 20 II.2.4 Preparation and transformation of E. coli DH5 competent cells ... 21 II.2.5 Preparation and transformation of S. pyogenes competent cells ...... 21 II.2.6 Quantitative co-culture and transwell system .................................. 22 II.2.7 Bacteriocin assay .............................................................................. 23 II.2.8 Growth curve measurement ............................................................. 23 i Table of content II.2.9 Quantitative assays for sagA-luciferase activity .............................. 23 II.2.10 Hemolysis assay ............................................................................... 24 II.2.11 Coaggregation assay (modified from Cisar et al., 1979) ................. 24 II.2.12 Biofilm quantification with safranin assay ....................................... 25 II.2.13 Microscopic observation and documentation of biofilms (Fluorescence, SEM, CLSM) ........................................................... 25 II.2.13.1 Fluorescence microscopy ............................................... 25 II.2.13.2 Scanning Electron Microscopy (SEM) .......................... 25 II.2.13.3 Confocal Laser Scanning Microscope (CLSM) ............. 26 II.2.14 Adherence and internalization assay ................................................ 26 II.2.15 Eukaryotic cell viability assay .......................................................... 27 II.2.16 Double-immunofluorescence assay .................................................. 28 II.2.17 HEp-2 cells microarray .................................................................... 29 III. Results ................................................................................................................... 31 III.1 S. pyogenes co-culture experiments: direct and indirect contact ................. 31 III.2 Bacteriocin assay .......................................................................................... 35 III.3 Effect on S. pyogenes sagA transcription ..................................................... 35 III.3.1 Construction of an S. pyogenes serotype M6 sagA-luc reporter gene strain ........................................................................................ 36 III.3.2 sagA-luc activity measurement in the presence of selected oral bacteria and E. coli Nissle ................................................................ 39 III.4 Effect of spent medium on S. pyogenes hemolytic activity ......................... 42 III.5 Coaggregation of S. pyogenes with oral bacteria and E. coli Nissle ............ 42 III.6 Effect of oral bacteria and E. coli Nissle on S. pyogenes biofilms ............... 43 III.6.1 Evaluation of growth medium and monospecies biofilm behaviour .......................................................................................... 44 III.6.2 Investigation of mixed-species biofilms .......................................... 46 III.6.3 The effect of artificial saliva on the species interaction ................... 50 III.7 Effect of oral bacteria and E. coli Nissle on S. pyogenes adherence to and internalization into host cells ........................................................................ 53 III.7.1 Quantitative assay ............................................................................ 53 III.7.2 Double immunofluorescence ............................................................ 59 III.8 Effect of oral bacteria and E. coli Nissle on S. pyogenes cytotoxicity ......... 61 III.9 Transcriptional response of HEp-2 cells in the presence of S. salivarius and S. oralis .................................................................................................. 63 ii Table of content IV. Discussion ............................................................................................................. 68 IV.1 General considerations ................................................................................. 68 IV.2 Changes of S. pyogenes numbers and viability in co-culture experiments 69 IV.3 Co-culture effects on S. pyogenes virulence factor expression .................... 71 IV.4 Co-culture effects on S. pyogenes biofilms .................................................. 73 IV.5 Co-culture effects on S. pyogenes interactions with eukaryotic cells .......... 75 IV.6 Co-culture effects on the integrity and metabolism of eukaryotic cells ....... 78 V. Conclusion ............................................................................................................. 82 VI. Reference ............................................................................................................... 84 VII. Appendix ............................................................................................................... 95 iii Abbreviations Abbreviations aad9 resistance gene for spectinomycin ATCC American Type Culture Collection aqua dest. aqua destillata bar pressure unit BHI Brain Heart Infusion bp base pair BSA bovine serume albumin C Coulomb, international unit for electric charge °C Celcius centigrade CaCl2 calciumchloride cfu colony forming unit CLSM Confocal Laser Scanning Microscopy CO2 carbondioxide Col collagen cpa gene encoding collagen binding protein DMEM Dulbecco’s modified Eagle’s medium DNA deoxyribonucleic acid dNTP dideoxynucleosidetriphosphate DSMZ Deutsche Sammlung für Mikroorganismen und Zellkulturen (German Collection of Microorganisms and Cell Cultures) E. coli Escherichia coli E. faecalis Enterococcus faecalis EDTA ethylene diamine tetraacetic acid emm gene encoding M protein EPS exopolysaccharide EtBr ethidiumbromide fbp gene encoding
Recommended publications
  • The Ecology of Staphylococcus Species in the Oral Cavity
    J. Med. Microbiol. Ð Vol. 50 2001), 940±946 # 2001 The Pathological Society of Great Britain and Ireland ISSN 0022-2615 REVIEW ARTICLE The ecology of Staphylococcus species in the oral cavity A. J. SMITH, M. S. JACKSON and J. BAGG Infection Research Group, Glasgow Dental Hospital and School, 378 Sauchiehall Street, Glasgow G2 3JZ Whilst the diversity of organisms present in the oral cavity is well accepted, there remains considerable controversy as to whether Staphylococcus spp. play a role in the ecology of the normal oral ¯ora. Surprisingly little detailed work has been performed on the quantitative and qualitative aspects of colonisation or infection either by coagulase- negative staphylococci CNS) or S. aureus. The latter is especially interesting in the light of present dif®culties in eradicating carriage of methicillin-resistant S. aureus MRSA) from the oropharynx in affected individuals. This paper reviews the current knowledge of staphylococcal colonisation and infection of the oral cavity in health and disease. S. aureus has been isolated from a wide range of infective oral conditions, such as angular cheilitis and parotitis. More recently, a clinical condition classi®ed as staphylococcal mucositis has emerged as a clinical problem in many debilitated elderly patients and those with oral Crohn's disease. Higher carriage rates of both CNS or S. aureus,or both, in patients prone to joint infections raises the interesting possibility of the oral cavity serving as a potential source for bacteraemic spread to compromised joint spaces. In conclusion, there is a surprising paucity of knowledge regarding the role of oral staphylococci in both health and disease.
    [Show full text]
  • Biofire Blood Culture Identification System (BCID) Fact Sheet
    BioFire Blood Culture Identification System (BCID) Fact Sheet What is BioFire BioFire BCID is a multiplex polymerase chain reaction (PCR) test designed to BCID? identify 24 different microorganism targets and three antibiotic resistance genes from positive blood culture bottles. What is the purpose The purpose of BCID is to rapidly identify common microorganisms and of BCID? antibiotic resistance genes from positive blood cultures so that antimicrobial therapy can be quickly optimized by the physician and the antibiotic stewardship pharmacist. It is anticipated that this will result in improved patient outcomes, decreased length of stay, improved antibiotic stewardship, and decreased costs. When will BCID be BCID is performed on all initially positive blood cultures after the gram stain is routinely performed and reported. performed? When will BCID not For blood cultures on the same patient that subsequently become positive with be routinely a microorganism showing the same morphology as the initial positive blood performed? culture, BCID will not be performed. BCID will not be performed on positive blood cultures with gram positive bacilli unless Listeria is suspected. BCID will not be performed on blood culture bottles > 8 hours after becoming positive. BCID will not be performed between 10PM-7AM on weekdays and 2PM-7AM on weekends. BCID will not be performed for clinics that have specifically opted out of testing. How soon will BCID After the blood culture becomes positive and the gram stain is performed and results be available? reported, the bottle will be sent to the core Microbiology lab by routine courier. BCID testing will then be performed. It is anticipated that total turnaround time will generally be 2-3 hours after the gram stain is reported.
    [Show full text]
  • Goals of This Review Testable Concepts Fundamentals: Host
    41a –Infections in the Neutropenic Cancer Patient and Hematopoietic Stem Cell Recipients Speaker: Kieren Marr, MD Disclosures of Financial Relationships with Relevant Commercial Interests • Consultant – Amplyx, Cidara, Merck and Company, Infections in the Neutropenic Cancer Patient and Sfunga Therapeutics Hematopoietic Stem Cell Recipients • Ownership Interests – MycoMed Technologies Kieren Marr, MD Professor of Medicine and Oncology John Hopkins University School of Medicine Director, Transplant and Oncology Infectious Diseases John Hopkins University School of Medicine Goals of This Review Testable Concepts • Immune compromised people develop “typical” • Think about the patient infections and those specific to their underlying risks – How does underlying disease impact risks? • Focus here on testable complications specific to the • Think about the treatment received host – What type of immune suppression? – Types of immune – suppressing drugs and diseases • Think about infections breaking through preventative – Recognition of specific “neutropenic syndromes” therapies • Skin lesions – A good context to test resistance and differentials • Invasive fungal infections • Think about common non‐infectious syndromes • Neutropenic colitis Fundamentals: Host Immune Risks Classic Immunologic risks • Immune defects associated with underlying • Neutropenia malignancy (and prior therapies) – Prolonged (>10 days) and profound (< 500 cells / mm3) – AML and myelodysplastic syndromes (MDS) associated with high risks for severe bacterial and fungal •
    [Show full text]
  • Pdfs/ Ommended That Initial Cultures Focus on Common Pathogens, Pscmanual/9Pscssicurrent.Pdf)
    Clinical Infectious Diseases IDSA GUIDELINE A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiologya J. Michael Miller,1 Matthew J. Binnicker,2 Sheldon Campbell,3 Karen C. Carroll,4 Kimberle C. Chapin,5 Peter H. Gilligan,6 Mark D. Gonzalez,7 Robert C. Jerris,7 Sue C. Kehl,8 Robin Patel,2 Bobbi S. Pritt,2 Sandra S. Richter,9 Barbara Robinson-Dunn,10 Joseph D. Schwartzman,11 James W. Snyder,12 Sam Telford III,13 Elitza S. Theel,2 Richard B. Thomson Jr,14 Melvin P. Weinstein,15 and Joseph D. Yao2 1Microbiology Technical Services, LLC, Dunwoody, Georgia; 2Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; 3Yale University School of Medicine, New Haven, Connecticut; 4Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland; 5Department of Pathology, Rhode Island Hospital, Providence; 6Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill; 7Department of Pathology, Children’s Healthcare of Atlanta, Georgia; 8Medical College of Wisconsin, Milwaukee; 9Department of Laboratory Medicine, Cleveland Clinic, Ohio; 10Department of Pathology and Laboratory Medicine, Beaumont Health, Royal Oak, Michigan; 11Dartmouth- Hitchcock Medical Center, Lebanon, New Hampshire; 12Department of Pathology and Laboratory Medicine, University of Louisville, Kentucky; 13Department of Infectious Disease and Global Health, Tufts University, North Grafton, Massachusetts; 14Department of Pathology and Laboratory Medicine, NorthShore University HealthSystem, Evanston, Illinois; and 15Departments of Medicine and Pathology & Laboratory Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey Contents Introduction and Executive Summary I.
    [Show full text]
  • The C-Di-Gmp Regulatory Network in Clostridioides Difficile and Its Role in Modulating Surface Adherence and Persistence in the Mammalian Gut
    THE C-DI-GMP REGULATORY NETWORK IN CLOSTRIDIOIDES DIFFICILE AND ITS ROLE IN MODULATING SURFACE ADHERENCE AND PERSISTENCE IN THE MAMMALIAN GUT Robert Woodrow McKee A dissertation submitted to the faculty at the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Doctor in Philosophy in the Department of Microbiology and Immunology. Chapel Hill 2018 Approved by: Peggy A Cotter Jonathan J. Hansen Virginia L. Miller Rita Tamayo Mathew C Wolfgang © 2018 Robert Woodrow McKee ALL RIGHTS RESERVED ii ABSTRACT Robert Woodrow McKee: The c-di-GMP regulatory network in Clostridioides difficile and its role in modulating surface adherence and persistence in the mammalian gut (Under the direction of Rita Tamayo) Clostridioides difficile (Clostridium difficile) is a spore-forming bacterial pathogen responsible for hundreds of thousands of infections each year in the United States. C. difficile outbreaks are common in hospitals because C. difficile spores can persist for months on surfaces and are resistant to many disinfectants. Despite the significant disease burden that C. difficile represents, we know surprisingly little about the factors necessary for C. difficile to colonize and persist in the mammalian intestine. Previous work demonstrated that the signaling molecule cyclic diguanylate (c-di-GMP) regulates a variety of processes in C. difficile including production of the toxins that are required for disease symptoms. Using monolayers of human intestinal epithelial cells, we demonstrate that c-di-GMP promotes attachment of C. difficile to intestinal epithelial cells. We also demonstrate that regulation of type IV pili (TFP) by c-di-GMP promotes prolonged adherence of C.
    [Show full text]
  • Common Commensals
    Common Commensals Actinobacterium meyeri Aerococcus urinaeequi Arthrobacter nicotinovorans Actinomyces Aerococcus urinaehominis Arthrobacter nitroguajacolicus Actinomyces bernardiae Aerococcus viridans Arthrobacter oryzae Actinomyces bovis Alpha‐hemolytic Streptococcus, not S pneumoniae Arthrobacter oxydans Actinomyces cardiffensis Arachnia propionica Arthrobacter pascens Actinomyces dentalis Arcanobacterium Arthrobacter polychromogenes Actinomyces dentocariosus Arcanobacterium bernardiae Arthrobacter protophormiae Actinomyces DO8 Arcanobacterium haemolyticum Arthrobacter psychrolactophilus Actinomyces europaeus Arcanobacterium pluranimalium Arthrobacter psychrophenolicus Actinomyces funkei Arcanobacterium pyogenes Arthrobacter ramosus Actinomyces georgiae Arthrobacter Arthrobacter rhombi Actinomyces gerencseriae Arthrobacter agilis Arthrobacter roseus Actinomyces gerenseriae Arthrobacter albus Arthrobacter russicus Actinomyces graevenitzii Arthrobacter arilaitensis Arthrobacter scleromae Actinomyces hongkongensis Arthrobacter astrocyaneus Arthrobacter sulfonivorans Actinomyces israelii Arthrobacter atrocyaneus Arthrobacter sulfureus Actinomyces israelii serotype II Arthrobacter aurescens Arthrobacter uratoxydans Actinomyces meyeri Arthrobacter bergerei Arthrobacter ureafaciens Actinomyces naeslundii Arthrobacter chlorophenolicus Arthrobacter variabilis Actinomyces nasicola Arthrobacter citreus Arthrobacter viscosus Actinomyces neuii Arthrobacter creatinolyticus Arthrobacter woluwensis Actinomyces odontolyticus Arthrobacter crystallopoietes
    [Show full text]
  • Use of the Diagnostic Bacteriology Laboratory: a Practical Review for the Clinician
    148 Postgrad Med J 2001;77:148–156 REVIEWS Postgrad Med J: first published as 10.1136/pmj.77.905.148 on 1 March 2001. Downloaded from Use of the diagnostic bacteriology laboratory: a practical review for the clinician W J Steinbach, A K Shetty Lucile Salter Packard Children’s Hospital at EVective utilisation and understanding of the Stanford, Stanford Box 1: Gram stain technique University School of clinical bacteriology laboratory can greatly aid Medicine, 725 Welch in the diagnosis of infectious diseases. Al- (1) Air dry specimen and fix with Road, Palo Alto, though described more than a century ago, the methanol or heat. California, USA 94304, Gram stain remains the most frequently used (2) Add crystal violet stain. USA rapid diagnostic test, and in conjunction with W J Steinbach various biochemical tests is the cornerstone of (3) Rinse with water to wash unbound A K Shetty the clinical laboratory. First described by Dan- dye, add mordant (for example, iodine: 12 potassium iodide). Correspondence to: ish pathologist Christian Gram in 1884 and Dr Steinbach later slightly modified, the Gram stain easily (4) After waiting 30–60 seconds, rinse with [email protected] divides bacteria into two groups, Gram positive water. Submitted 27 March 2000 and Gram negative, on the basis of their cell (5) Add decolorising solvent (ethanol or Accepted 5 June 2000 wall and cell membrane permeability to acetone) to remove unbound dye. Growth on artificial medium Obligate intracellular (6) Counterstain with safranin. Chlamydia Legionella Gram positive bacteria stain blue Coxiella Ehrlichia Rickettsia (retained crystal violet).
    [Show full text]
  • A Prospective Role for the Rumen in Generating Antibiotic Resistance 2 3 Cameron R
    bioRxiv preprint doi: https://doi.org/10.1101/729681; this version posted August 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 TITLE: A prospective role for the rumen in generating antibiotic resistance 2 3 Cameron R. Strachan1,4,*, Anna J. Mueller2, Mahdi Ghanbari3, Viktoria Neubauer4, Benjamin 4 Zwirzitz1,4, Sarah Thalguter1,4, Monika Dziecol4, Stefanie U. Wetzels4, Jürgen Zanghellini5,6,7, 5 Martin Wagner1, 4, Stephan Schmitz-Esser8, Evelyne Mann4 6 7 1FFoQSI GmbH, Technopark 1C, 3430 Tulln, Austria 8 2University of Vienna, Centre for Microbiology and Environmental Systems Science, 9 Division of Microbial Ecology, Althanstrasse 14, 1090 Vienna, Austria 10 11 3BIOMIN Research Center, Technopark 1, 3430, Tulln, Austria 12 13 4Institute of Food Safety, Food Technology and Veterinary Public Health, Department for Farm 14 Animals and Public Health, University of Veterinary Medicine Vienna, Veterinärplatz 1, 1210 15 Vienna, Austria 16 17 5Austrian Centre of Industrial Biotechnology, 1190 Vienna, Austria 18 19 6Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, 1190 20 Vienna, Austria 21 22 7Austrian Biotech University of Applied Sciences, 3430 Tulln, Austria 23 24 8Department of Animal Science, Iowa State University, 3222 National Swine Research and 25 Information Center, 1029 North University Blvd, Ames, IA 50011-3611, USA. 26 27 *Author correspondence: [email protected] 28 29 ABSTRACT 30 31 Antibiotics were a revolutionary discovery of the 20th century, but the ability of bacteria to 32 spread the genetic determinants of resistance via horizontal gene transfer (HGT) has quickly 33 endangered their use1.
    [Show full text]
  • New Guidelines for the Antibiotic Treatment of Streptococcal, Enterococcal and Staphylococcal Endocarditis
    Journal of Antimicrobial Chemotherapy (1998) 42, 292–296 JAC New guidelines for the antibiotic treatment of streptococcal, enterococcal and staphylococcal endocarditis D. C. Shanson Microbiology Department, Unilabs Clinical Trials International Central Laboratory Services, Bewlay House, 32 Jamestown Road, London NW1 7BY, UK Revised guidelines for the treatment of bacterial endo- mended in the USA during the last 20 years but were not carditis have recently been issued by the BSAC Working previously advocated in the UK.2,6 Many reports indicate Party,1 complementing previous recommendations from that a combination of penicillin plus an aminoglycoside the American Heart Association (AHA).2 The AHA kills penicillin-sensitive viridans streptococci more rapidly guidelines do not include empirical treatment recommen- than penicillin alone, and that a 2-week course of penicillin dations, perhaps implying that the results of blood cultures plus streptomycin is effective clinically.2,6 Gentamicin is, should be awaited, which is not usually the policy in the however, generally the preferred aminoglycoside as it is UK. Apart from these differences, the two reports, which much more often used in general clinical practice than were initiated by independent working groups, include streptomycin, convenient to give by the intravenous route, broadly similar recommendations. In both publications, and more readily assayed than streptomycin. In-vitro and antibiotic treatment is indicated for patients with a in-vivo experimental data support the use of gentamicin diagnosis of infective endocarditis based on the Duke as an alternative to streptomycin for short-course treat- diagnostic criteria,3,4 and early surgical intervention is ment;2,7 there is a relative lack of clinical reports on emphasized for some patients, especially if their 2-week treatment courses using gentamicin instead of haemodynamic condition deteriorates.
    [Show full text]
  • Streptococci
    STREPTOCOCCI Streptococci are Gram-positive, nonmotile, nonsporeforming, catalase-negative cocci that occur in pairs or chains. Older cultures may lose their Gram-positive character. Most streptococci are facultative anaerobes, and some are obligate (strict) anaerobes. Most require enriched media (blood agar). Streptococci are subdivided into groups by antibodies that recognize surface antigens (Fig. 11). These groups may include one or more species. Serologic grouping is based on antigenic differences in cell wall carbohydrates (groups A to V), in cell wall pili-associated protein, and in the polysaccharide capsule in group B streptococci. Rebecca Lancefield developed the serologic classification scheme in 1933. β-hemolytic strains possess group-specific cell wall antigens, most of which are carbohydrates. These antigens can be detected by immunologic assays and have been useful for the rapid identification of some important streptococcal pathogens. The most important groupable streptococci are A, B and D. Among the groupable streptococci, infectious disease (particularly pharyngitis) is caused by group A. Group A streptococci have a hyaluronic acid capsule. Streptococcus pneumoniae (a major cause of human pneumonia) and Streptococcus mutans and other so-called viridans streptococci (among the causes of dental caries) do not possess group antigen. Streptococcus pneumoniae has a polysaccharide capsule that acts as a virulence factor for the organism; more than 90 different serotypes are known, and these types differ in virulence. Fig. 1 Streptococci - clasiffication. Group A streptococci causes: Strep throat - a sore, red throat, sometimes with white spots on the tonsils Scarlet fever - an illness that follows strep throat. It causes a red rash on the body.
    [Show full text]
  • Rapid Differentiation of Pneumococci
    Department of Microbiology University of Helsinki Helsinki, Finland RAPID DIFFERENTIATION OF PNEUMOCOCCI AND VIRIDANS GROUP STREPTOCOCCI BY MALDI-TOF MASS SPECTROMETRY AND A RAPID NUCLEIC ACID AMPLIFICATION TEST IN A CLINICAL MICROBIOLOGY LABORATORY Inka Harju ACADEMIC DISSERTATION To be presented, with the permission of the Faculty of Agriculture and Forestry, the University of Helsinki, for public examination in Lecture hall 2 (235), Infocenter Corona, Viikinkaari 11, on 14 June 2019, at 12 noon. Helsinki 2019 ISBN 978-951-51-5272-5 (print) ISBN 978-951-51-5273-2 (PDF) Dissertationes Schola Doctoralis Scientiae Circumiectalis, Alimentariae, Biologicae 13/2019 ISSN 2342-5423 (print) ISSN 2342-5431 (Online). Unigrafia Helsinki 2019 ABSTRACT Streptococcus pneumoniae is one of the most significant human bacterial pathogens. It is a major causative agent of community-acquired pneumonia. It is also the most common cause of bacterial otitis media and among most common bacteria causing meningitis in children. The close relatives of S. pneumoniae, the Viridans group streptococci form a central part of the human oral microbiome, but they are also a leading cause of endocarditis. The fast and reliable identification of these bacteria from clinical specimens would therefore be of prime importance for a clinical microbiology laboratory, allowing for the laboratory to provide helpful information to clinicians for identifying the infection focus and targeting antibiotic treatment. The close relationship between S. pneumoniae and Viridans group streptococci, especially their subgroup Mitis group streptococci, complicates the reliable species level identification of these bacteria. The identification of streptococci by the traditional biochemical methods is both unreliable and time-consuming: the identification takes 1-2 days after bacterial growth has been detected on a plate or in a blood culture bottle.
    [Show full text]
  • Identification of Clinically Relevant Streptococcus and Enterococcus
    pathogens Article Identification of Clinically Relevant Streptococcus and Enterococcus Species Based on Biochemical Methods and 16S rRNA, sodA, tuf, rpoB, and recA Gene Sequencing Maja Kosecka-Strojek 1,* , Mariola Wolska 1, Dorota Zabicka˙ 2 , Ewa Sadowy 3 and Jacek Mi˛edzobrodzki 1 1 Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, 30-387 Krakow, Poland; [email protected] (M.W.); [email protected] (J.M.) 2 Department of Molecular Microbiology, National Medicines Institute, 00-725 Warsaw, Poland; [email protected] 3 Department of Epidemiology and Clinical Microbiology, National Medicines Institute, 00-725 Warsaw, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-12-664-6365 Received: 13 October 2020; Accepted: 9 November 2020; Published: 11 November 2020 Abstract: Streptococci and enterococci are significant opportunistic pathogens in epidemiology and infectious medicine. High genetic and taxonomic similarities and several reclassifications within genera are the most challenging in species identification. The aim of this study was to identify Streptococcus and Enterococcus species using genetic and phenotypic methods and to determine the most discriminatory identification method. Thirty strains recovered from clinical samples representing 15 streptococcal species, five enterococcal species, and four nonstreptococcal species were subjected to bacterial identification by the Vitek® 2 system and Sanger-based sequencing methods targeting the 16S rRNA, sodA, tuf, rpoB, and recA genes. Phenotypic methods allowed the identification of 10 streptococcal strains, five enterococcal strains, and four nonstreptococcal strains (Leuconostoc, Granulicatella, and Globicatella genera). The combination of sequencing methods allowed the identification of 21 streptococcal strains, five enterococcal strains, and four nonstreptococcal strains.
    [Show full text]